Abstract
In this manuscript, we review the literature on the nutrigenetics and pharmacogenetics of vitamin D pathways, with a focus on genes involved in the pharmacokinetic and pharmacodynamic pathways of vitamin D as they have been major research targets. These include: VDR, CYP2R1, CYP27B1, DHCR7/NADSYN1, GC and CYP24A1. So far only 2 genome wide associations studies evaluated the potential role of genetic polymorphisms in the variability in 25 hydroxy vitamin D (25(OH)D) levels. Most of the evidence is based on the candidate gene approach with some conflicting results when it comes to effect size and associating disease outcome with 25(OH)D levels and genetic polymorphisms. Moreover, very little has been done to look at the effect of significant polymorphisms on the response to vitamin D supplementation. Further research is needed on larger population samples of different ethnicities to resolve some of the controversies. In addition, emerging technologies such as next generation sequencing may be a better genotyping alternative in order to detect rare but potentially important genetic variants. Functional studies are also needed to better understand the association results. This includes coupling genotyping data with gene expression studies as well as epigenetic evaluations.
Keywords: Cytochrome P450, epigenetics, nutrigenetics, pharmacogenetics, vitamin D - 25(OH)D.
Current Pharmacogenomics and Personalized Medicine
Title:The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Volume: 12 Issue: 2
Author(s): Zainab Awada, Safaa Ossaily and Nathalie K. Zgheib
Affiliation:
Keywords: Cytochrome P450, epigenetics, nutrigenetics, pharmacogenetics, vitamin D - 25(OH)D.
Abstract: In this manuscript, we review the literature on the nutrigenetics and pharmacogenetics of vitamin D pathways, with a focus on genes involved in the pharmacokinetic and pharmacodynamic pathways of vitamin D as they have been major research targets. These include: VDR, CYP2R1, CYP27B1, DHCR7/NADSYN1, GC and CYP24A1. So far only 2 genome wide associations studies evaluated the potential role of genetic polymorphisms in the variability in 25 hydroxy vitamin D (25(OH)D) levels. Most of the evidence is based on the candidate gene approach with some conflicting results when it comes to effect size and associating disease outcome with 25(OH)D levels and genetic polymorphisms. Moreover, very little has been done to look at the effect of significant polymorphisms on the response to vitamin D supplementation. Further research is needed on larger population samples of different ethnicities to resolve some of the controversies. In addition, emerging technologies such as next generation sequencing may be a better genotyping alternative in order to detect rare but potentially important genetic variants. Functional studies are also needed to better understand the association results. This includes coupling genotyping data with gene expression studies as well as epigenetic evaluations.
Export Options
About this article
Cite this article as:
Awada Zainab, Ossaily Safaa and Zgheib K. Nathalie, The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways, Current Pharmacogenomics and Personalized Medicine 2014; 12 (2) . https://dx.doi.org/10.2174/1875692112666140529002223
DOI https://dx.doi.org/10.2174/1875692112666140529002223 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Umbilical Cord Tissue Mesenchymal Stem Cells: Characterization and Clinical Applications
Current Stem Cell Research & Therapy Editorial: Conventional, Traditional and Alternative Therapies for Cardiovascular Disorders. Part 1: Conventional Therapy
Current Pharmaceutical Design Therapeutic Potential of Stem/Progenitor Cells in Human Skeletal Muscle for Cardiovascular Regeneration
Current Stem Cell Research & Therapy Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews Postprandial Glucose - A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Vascular Pharmacology F508del-CFTR Rescue: A Matter of Cell Stress Response
Current Pharmaceutical Design Clozapine Safety, 40 Years Later
Current Drug Safety Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?
Current Medicinal Chemistry Statins: A Valuable Tool for the Prevention/Regression of Abdominal Aortic Aneurysms
Vascular Disease Prevention (Discontinued) Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Optimal Management of Hypertension in patients with Ischemic Heart Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Editorial [Hot topic: MicroRNAs: from Basic Regulation Towards Therapeutic Approaches - Passion, Caution and Patience Required (Guest Editor: Dr. Thomas Thum)]
Current Drug Targets The Role of Neopterin in Atherogenesis and Cardiovascular Risk Assessment
Current Medicinal Chemistry Preconditioning with Chronic Cerebral Hypoperfusion Reduces a Focal Cerebral Ischemic Injury and Increases Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 and Matrix Metalloproteinase-2 Expression
Current Neurovascular Research Are Carbonic Anhydrase Inhibitors Suitable for Obtaining Antiobesity Drugs ?
Current Pharmaceutical Design Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Pharmacotherapy in Systemic Lupus Erythematosus
Current Rheumatology Reviews